Marine Drugs · 2012 · 13 citations · 15 references
MedicineMedicinal ChemistryPharmacologyCancer PharmacologyChemotherapyDrug DiscoveryFungal Secondary MetabolitesMarine Bioactive CompoundsMarine Drug DiscoveryMarine PharmacologyOncology PharmacologyAnticancer Compound ScreeningAnticancer Marine CompoundsBioactive Compounds From Marine FungiBioactive Marine MetabolitesCytotoxicity AssaysMarine Fungal Natural ProductsMarine Fungi As Drug SourcesMarine-derived Anticancer Compounds
Deoxybostrycin (1) is an anthraquinone compound derived from the marine mangrove fungus Nigrospora sp. No. 1403 and has potential to be a lead for new drugs because of its various biological properties. A series of new derivatives (2-22) of deoxybostrycin were synthesized. The in vitro cytotoxicity of all the new compounds was tested against MDA-MB-435, HepG2 and HCT-116 cancer cell lines. Most of the compounds exhibit strong cytotoxicity with IC₅₀ values ranging from 0.62 to 10 μM. Compounds 19, 21 display comparable cytotoxicity against MDA-MB-435 to epirubicin, the positive control. The primary screening results indicate that the deoxybostrycin derivatives might be a valuable source of new potent anticancer drug candidates.
15
Deaths: leading causes for 2004.
Melonie Heron · PubMed · 2007 · 235 citations
Public Health, Pediatrics, Clinical Classification Systems +16
Marine-derived anticancer agents in clinical trials
Gilberto Schwartsmann, Adriana Brondani da Rocha, Jane Mattei et al. · Expert Opinion on Investigational Drugs · 2003 · 91 citations
Medicine, Oncology, Pharmacology +14
Deaths: leading causes for 2005.
Melonie Heron, Betzaida Tejada‐Vera · PubMed · 2009 · 86 citations
Lei Wang, Dahong Li, Shengtao Xu et al. · European Journal of Medicinal Chemistry · 2012 · 70 citations